Searchable abstracts of presentations at key conferences in endocrinology

ea0090p406 | Pituitary and Neuroendocrinology | ECE2023

Somatotroph Pituitary Neuroendocrine Tumors (Pitnets)/Adenomas Expressing Steroidogenic Factor (SF1)

Guaraldi Federica , Roncaroli Federico , Villa Chiara , Zoli Matteo , Waqar Mueez , Higham Claire , Lally Imogen , Baussart Bertrand , Assie Guillaume , Morandi Luca , Mazzatenta Diego , Asioli Sofia

Rationale and aim: A recent pangenomic study documented a subset of somatotroph mostly GNAS-wildtype PitNET/adenomas co-express steroidogenic factor 1 (SF1). Aim of our study was to investigate clinical and molecular features of a cohort of these tumour subtype. Study sample: We identified 20 cases of SF1-expressing somatotropinomas out of 173 (11.6%) operated via transsphenoidal endoscopic approach in 3 referral Pituitary Centers patients. Pre- and post...

ea0065op6.2 | Neuroendocrinology, Pituitary and Neoplasia | SFEBES2019

Transcriptomic analyses reveal deregulation of focal adhesion pathway in Aip KO mice and AIP mutation positive human tumours

Bollington Mark , Mistry Anisha , Solomou Antonia , Barry Sayka , Begalli Federica , Vignola Maria , Lim Chung Thong , Herincs Maria , Roncaroli Federico , Gaston-Massuet Carles , Korbonits Marta

Introduction: AIP mutations are responsible for 15-30% of cases of familial isolated pituitary adenomas. The pathophysiology that drives this AIP-related pituitary tumorigenesis is not fully understood. We developed a pituitary-specific Aip knockout (KO) mouse model, which mostly recapitulates the human phenotype.Aims: To performed comparative gene expression analysis of Aip-KO mouse pituitary tumours and AIP mutation positive ...

ea0067o46 | Oral Presentations | EYES2019

Effect of treatment with Cinacalcet on TBS and BMD in patients with chronic renal failure with secondary hyperparathyroidism in hemodialysis

Reyes Laura Mola , Maria Soledad Librizzi , Martinez Eduardo Hernandez , Herrero Eva Merida , Cuellar Hernando Trujillo , Arriscado Cristina Martin , Carranza Federico Hawkins

Background: Fractures are frequent in patients with chronic renal failure (CRF) with secondary hyperparathyroidism (SHPT) undergoing hemodialysis. Cinacalcet (CT) is a drug used in the reduction of hypercalcemia in these patients that acts through the lintel calcium sensor in the parathyroid gland. Recently, it has been pointed out that CT can reduce fractures in these patients by unknown mechanisms (EVOLVE Trials 2015).Objectives: To evaluate the effect...

ea0063gp59 | Acromegaly and GH | ECE2019

Effects of pegvisomant and pasireotide LAR on incidence of vertebral fractures in patients with acromegaly resistant to treatment with first-line somatostatin analogs

Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Bima Chiara , Frara Stefano , Mirra Federica , Donfrancesco Federico , Fleseriu Cara Maria , Fleseriu Maria , Giustina Andrea , Laura De Marinis , Pontecorvi Alfredo

Purpose: Osteopathy is an emerging complication of acromegaly characterized by increased bone turnover, deterioration in bone microarchitecture and high risk of vertebral fractures (VFs). In somatostatin analog (SSA)-resistant patients (pts), Pegvisomant (PegV) and Pasireotide LAR (Pasi) are used for acromegaly treatment, but their effect on skeletal health is still not defined.Methods: In a longitudinal international multicenter study, we evaluated inci...

ea0063p464 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

EGFR and IGF1R affect Sunitinib activity: novel targets for Broncho-Pulmonary Neuroendocrine Neoplasm treatment

Bresciani Giulia , Ditsiou Angeliki , Cilibrasi Chiara , Vella Viviana , Rea Federico , Schiavon Marco , Cavallesco Narciso Giorgio , Giamas Georgios , Zatelli Maria Chiara , Gagliano Teresa

Background: Available medical treatments for Broncho-Pulmonary Neuroendocrine Neoplasm (BP-NENs) derived from clinical trials are not specific for the management of this malignancy. Sunitinib, a multi-receptor tyrosine-kinases (RTKs) inhibitor, mainly described as VEGFR inhibitor, has shown its efficacy in Pancreatic NENs but there are not available data about its action in BP-NENs. Our aim was to understand the effects of RTKs inhibition promoted by Sunitinib in order to eval...

ea0049gp187 | Pituitary & endocrine Tumours | ECE2017

Pasireotide alone or in combination with cabergoline effectively controls urinary free cortisol levels: results from a prospective study in patients with Cushing’s disease (CAPACITY)

Pivonello Rosario , Kadioglu Pritam , Bex Marie , Devia Deyanira Gonzalez , Boguszewski Cesar , Yavuz Dilek Gogas , Patino Heather , Campigotto Federico , Pedroncelli Alberto , Fleseriu Maria , Biller Beverly M K , Feelders Richard

Background: Pasireotide is a multireceptor-targeted somatostatin analogue that predominantly binds to somatostatin receptor subtype 5 (SSTR5) and provides sustained control of urinary free cortisol (UFC) levels in some patients with Cushing’s disease (CD). Cabergoline is a dopamine D2 receptor agonist with efficacy in some patients with CD. Most corticotropinomas co-express SSTR5 and D2, providing rationale for combination treatment with pasireotide and cabergoline. Resul...

ea0049ep365 | Cardiovascular Endocrinology and Lipid Metabolism | ECE2017

Salivary lactate levels during anaerobic threshold (AT) training

Berea Hugo Ogando , Estevez Laura Toba , Gomez Juan Fandino , Chaves Yolanda Diz , Soidan Jose Luis Garcia , Matias Lucas Gonzalez , Ferrer Federico Mallo

Anaerobic threshold (AT) is defined as the point of maximum intensity at which lactate is being produced but does not accumulate in blood during exercise. Training at this intensity is common in athletes. Lactate is currently regard as indicator of effort intensity. It is usually quantified by reflectometry of capillary blood. This procedure although not very invasive, may be annoying during repeated measurements. Saliva is proposed as an alternative sample.<p class="abste...

ea0048o2 | Oral Communications | SFEEU2017

Metastatic pituitary carcinoma in an SDHB mutation positive patient

Tufton Nicola , Roncaroli Federico , Hadjudemetriou Irene , Dang Mary N , Denes Judit , Guasti Leonardo , Thom Maria , Powell Michael , Baldeweg Stephanie E , Fersht Naomi , Korbonits Marta

Case history: A 63-year-old female presented with bi-temporal hemianopia. Pituitary MRI demonstrated a macroadenoma with suprasellar extension. Her medical history included a glomus tumour of the right ear treated with external beam radiotherapy (EBRT) 25 years previously. She had no evidence of pituitary hormone abnormality and had normal urinary metanephrines levels. She underwent transsphenoidal surgery with total resection and full recovery of her visual fields. Immunohist...

ea0041ep40 | Adrenal cortex (to include Cushing's) | ECE2016

Analysis of 176 cases of adrenal incidentaloma investigated in a single clinical center, what are we doing?

Jimenez Maria Maiz , Gutierrez Maria Calatayud , Bracamonte Milagros Sierra , Librizzi Soledad , Nino Virginia Rodriguez , Munoz Myriam Lorena Partida , Carranza Federico Hawkins

Introduction: Patients referred for adrenal incidentalomas (AI) are increasing. Current guidelines are controversial on diagnosis and length of follow-up.Objectives: Analyze clinical, radiologic and hormonal characteristics of patients with AI. Evaluate the number and usefulness of tests needed for diagnosis, clinical outcome and follow up.Material and methods: Observational, retrospective study in patients with AI in our endocrino...

ea0041ep743 | Neuroendocrinology | ECE2016

Liraglutide restores the endocrine function of islet’s β-cells and the altered lipid profile in early stages of life induced by food restriction in pregnancy

Diz-Chaves Yolanda , Toba Laura , Fandino Juan , Ogando Hugo , Gonzalez-Nunez Maria , Romani Marina , Vigo Eva , Gonzalez-Matias Lucas , Mallo Federico

Maternal food restriction during late pregnancy and lactation, increases the risk of glucose intolerance and metabolic diseases such as diabetes & obesity in rats. Liraglutide is a GLP-1 receptor agonists administered for treating DM2. The aim of this study was to elucidate if liraglutide given to pregnant rats may prevent the deleterious effects of malnourishment in male pups analyzed at 21 days of age.Twenty eight Sprague-Dawley pregnant rats were ...